TNF and benign prostatic hyperplasia: Further evaluation of these drugs using chi-square or Fisher’s exact tests in patients with AI disease indicates that methotrexate use significantly increases BPH diagnosis (p < 0.0001) while the use of TNF-antagonists significantly decreases BPH diagnosis (p = 0.006) compared to patients without AI disease (Supplementary Table 9).